Anthony P. Mack - Jan 25, 2023 Form 4/A - Amendment Insider Report for Virpax Pharmaceuticals, Inc. (VRPX)

Role: Chief Executive Officer, Director, 10%+ Owner
Signature: /s/ Christopher Chipman, attorney-in-fact
Stock symbol: VRPX
Transactions as of: Jan 25, 2023
Transactions value $: $0
Form type: 4/A - Amendment
Date filed: 2/7/2023, 08:30 PM
Date Of Original Report: Jan 27, 2023
Previous filing: May 20, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VRPX	Stock Option (right to buy)	Award	$0	+125K		$0.00	125K	Jan 25, 2023	Common Stock	125K	$0.87	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option vests in three equal annual installments commencing on January 25, 2024.

Remarks:

This amendment on Form 4/A is being filed to amend the Form 4 filed on January 27, 2023, solely to correct inadvertent errors in the exercise price and expiration date of the Stock Option previously reported in Column 2 and Column 6 of Table II, respectively.